Australia's Mayne Pharma falls on lower unaudited revenue and earnings

Mayne Pharma

31/07/2026 03:56

** Shares of Australia's Mayne Pharma Group MYX.AX fall as much as 7.1% to A$2.415, marking their biggest intraday pct loss since March 19
** Shares hit their lowest level since June 26
** Specialty pharmaceutical co posts unaudited 4Q FY26 underlying EBITDA of A$4.6 million ($3.23 million), down 76% from A$19.3 million last year 
** Posts unaudited 4Q FY26 revenue of A$86.5 million, down 22% from A$110.7 million in 4Q 2025
** Co expects FY26 revenue to be A$383.7 million and underlying EBITDA to be A$31.7 million, down 6% and 33% on pcp, respectively
** Nearly 259,300 shares change hands, about 1.3x the 30-day average 
** Stock down 19.3% YTD, including session's moves

($1 = 1.4243 Australian dollars)

 (Reporting by Subhalakshmi Dey in Bengaluru)
 ((Subhalakshmi.Dey@thomsonreuters.com;))